There is also evidence that forced expression of cdk1-cyclin B attenuates drug sensitivity in glioma cells 20, and cyclin B overexpression in patients with head and neck squamous cell carcinoma has been correlated with poor therapeutic response 21. This evidence concerns the gene CDK1 and central nervous system cancer.